(MedPage Today) — Use of nivolumab (Opdivo) before chemotherapy was not associated with improved pathologic complete response (pCR) rates among patients with early triple-negative breast cancer (TNBC), but a 12-week non-anthracycline regimen in… Source link : https://www.medpagetoday.com/hematologyoncology/breastcancer/114604 Author : Publish date : 2025-03-11 20:39:00 Copyright for syndicated content belongs to the linked Source.
The post De-Escalated Neoadjuvant Chemoimmunotherapy Shows Promise in Early TNBC first appeared on News Health.
Author : News Health
Publish date : 2025-03-11 20:39:00
Copyright for syndicated content belongs to the linked Source.